Healthcare is a defensive sector that is more resilient to economic downturns than most others. That's one of several reasons ...

Bristol-Myers Squibb offers 17.25% upside with strong growth prospects, cost-saving initiatives & an undervalued stock. Learn ...

Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...

We came across a bullish thesis on Bristol-Myers Squibb Company (BMY) on Substack by Magnus Ofstad. In this article, we will ...

Bristol Myers Squibb Co. closed 5.27% below its 52-week high of $63.33, which the company reached on March 11th.

Bristol Myers Squibb, a global biopharmaceutical company, has appointed Osama Braiwish as its General Manager for Saudi ...

Thanks to the spending growth cap, the U.K. government in December 2024 announced that companies would need to pay a 22.9% ...

Bristol Myers (BMY)’ treatment of small cell lung cancer, atigotatug plus nivolumab fixed dose combination, received FDA orphan designation, ...

William Blair upped their Q2 2025 earnings estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, March ...

Bristol Myers Squibb Co. closed 6.82% below its 52-week high of $63.33, which the company reached on March 11th.

Despite advances in anticoagulant therapies, bleeding remains a critical concern.Traditionally, the definition of major ...

Pfizer stock has delivered its long-term shareholders a dividend that has grown for 16 consecutive years. The pace of those ...